SCHEMBL31435952

SCHEMBL31435952

CCc1[nH]c2ncc(-c3cn(C4CCN(C)CC4)nc3Cl)cc2c1-c1ccc(OC)nc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.37
LRRK2 Q5S007 1/20 0.37
MTOR P42345 2/20 0.36
TLR9 Q9NR96 2/20 0.36
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
IL2 P60568 1/20 0.34
MAP4K1 Q92918 1/20 0.34
INSR P06213 1/20 0.34
ALK Q9UM73 1/20 0.34
PAK1 Q13153 1/20 0.34
RET P07949 1/20 0.34
GSK3B P49841 1/20 0.34
DYRK1A Q13627 1/20 0.34
PIK3CA P42336 2/20 0.34
JAK2 O60674 1/20 0.34
RIOK2 Q9BVS4 1/20 0.34
FGFR3 P22607 2/20 0.33
MAP3K11 Q16584 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31435991 0.91 TLR9 (0.38) CHEK1MTORTLR9TLR8TLR7
SCHEMBL31435948 0.85 JAK2 (0.43) LRRK2ALKPAK1DYRK1AJAK2
SCHEMBL31435915 0.83 TLR9 (0.37) CHEK1MTORTLR9TLR8TLR7
SCHEMBL31435902 0.82 MAP4K1 (0.50) IL2MAP4K1INSRPAK1MAP3K11
SCHEMBL31435961 0.77 KCNH2 (0.38) LRRK2MTORMAP4K1RETPIK3CA
SCHEMBL31435951 0.77 JAK2 (0.39) ALKPAK1GSK3BDYRK1AJAK2
SCHEMBL31435941 0.76 AXL (0.32) CHEK1IL2MAP4K1RETGSK3B
SCHEMBL31435913 0.74 MAP4K1 (0.48) IL2MAP4K1INSRMAP3K11TDO2
SCHEMBL31435931 0.73 MAP4K1 (0.51) IL2MAP4K1DYRK1AMAP3K11TDO2
SCHEMBL31435918 0.73 MAP4K1 (0.51) IL2MAP4K1DYRK1AMAP3K11TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2025-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS TYRO3, TH, TYR CHEK1 2623/4885LRRK2 515/4885MTOR 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.